ArticleJournal of pharmacy & bioallied sciences2025
A Study of Cutaneous Manifestations in Patients During the Post-COVID Period in A Tertiary Care Center.
Article in Journal of pharmacy & bioallied sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The post-COVID period has been associated with various systemic complications, including dermatological manifestations. Understanding the spectrum of cutaneous manifestations following coronavirus disease of 2019 (COVID-19) infection is essential for early diagnosis and appropriate management. This study aims to assess the prevalence and types of cutaneous manifestations in patients recovering from COVID-19 at a tertiary care center. Methods: A cross-sectional observational study was conducted at the Dermatology, Venereology, and Leprosy (DVL) outpatient department of Bharati Vidyapeeth (Deemed to be University) Medical College and Hospital, Sangli, over a period of 6 months. A total of 50 patients presenting with new or worsening cutaneous symptoms at least 4 weeks after COVID-19 recovery were included. Clinical and demographic data were documented, and dermatological examinations were performed. Results: The most commonly observed cutaneous manifestation was telogen effluvium (30%), followed by herpes infection (20%), acne (16%), and pityriasis rosea (6%). Other conditions included lichen planus, psoriasis, vasculitis, erythema multiforme, vitiligo, and dermatomyositis. Middle-aged individuals were predominantly affected, and females exhibited a higher prevalence (58%) than males (42%). Conclusion: Post-COVID cutaneous manifestations exhibit a diverse range of presentations, necessitating a multidisciplinary approach for timely recognition and intervention. Further studies with larger sample sizes are required to establish potential mechanisms linking COVID-19 with dermatological sequelae.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.